Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.
This study characterizes the previously reported anti-canine CD20 antibody 4E1-7-B_f and compares this with commercially available anti-human CD20 antibodies, rituximab and an obinutuzumab biosimilar. While the obinutuzumab biosimilar exhibited binding to canine CD20 in a CD20-transduced cell line,...
Saved in:
| Main Authors: | Takuya Mizuno, Yukinari Kato, Toshihiro Tsukui, Masaya Igase |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0325526 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma
by: Mihaljević Biljana, et al.
Published: (2008-01-01) -
Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis
by: Decimo Silvio Chiarenza, et al.
Published: (2025-01-01) -
Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients
by: Peng Sun, et al.
Published: (2025-06-01) -
Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra
by: K. A. Sychevskaya, et al.
Published: (2022-04-01) -
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis
by: Alice G. Willison, et al.
Published: (2025-04-01)